Humacyte Inc (HUMA)

$1.01 0.00 (N/A)
Market Cap 189.14M
Revenue (ttm) 0.00
Net Income (ttm) -148.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,479,900
Avg Vol 5,417,236
Day's Range N/A - N/A
Shares Out 187.27M
Stochastic %K 32%
Beta 1.93
Analysts Strong Sell
Price Target $7.71

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 313 9633
Address:
2525 East North Carolina Highway 54, Durham, United States
Rolf1968
Rolf1968 Feb. 15 at 12:42 AM
$HUMA off the shelf biological conduit is the holy grail
0 · Reply
MeetMillz732
MeetMillz732 Feb. 14 at 4:33 PM
$HUMA Humacyte (HUMA) Valuation Check As DoD Funding Highlights Battlefield Vascular Repair Potential https://share.google/qFc33zd7PXNCp7Yn5
0 · Reply
Q12021Dreaming
Q12021Dreaming Feb. 14 at 2:54 PM
$HUMA - Shorts are betting on a dilution death spiral that DoD funding ELIMINATED. They're fighting the: U.S. Department of Defense Congressional mandate FDA-approved monopoly $77.5M credit facility Battle-tested technology At $1.01, with 20.77% short interest, this is a ticking time bomb. When shorts realize they can't win, the covering cascade will be EPIC.
1 · Reply
fatpie68
fatpie68 Feb. 14 at 12:23 PM
$HUMA Institutional Ownership increased 1.43% over the past week.
0 · Reply
thrivegan86
thrivegan86 Feb. 14 at 2:09 AM
$HUMA = 100% of my portfolio. Boom or bust!
1 · Reply
Invest2live
Invest2live Feb. 14 at 12:01 AM
$ELUT 51% in a month already; congrats 🌿🎈🌿 Checkout $HUMA and $GERN
0 · Reply
Bad_Choices
Bad_Choices Feb. 13 at 10:48 PM
$HUMA it will just bar code around this area for a while until news.
0 · Reply
fordsurf
fordsurf Feb. 13 at 8:27 PM
$HUMA Sitting on 3300 at $6.25. Thinking it’s about time to start avg down. Come april / may…forget about it.
1 · Reply
BZT777
BZT777 Feb. 13 at 8:16 PM
$HUMA The big boys continued to add more HUMA in Q4 2025
0 · Reply
Bio_Be_Dirty
Bio_Be_Dirty Feb. 13 at 6:58 PM
$HUMA sales starting to pile
0 · Reply
Latest News on HUMA
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Feb 9, 2026, 8:00 AM EST - 5 days ago

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

Jan 8, 2026, 8:00 AM EST - 5 weeks ago

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

Jan 5, 2026, 8:00 AM EST - 5 weeks ago

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Dec 22, 2025, 8:00 AM EST - 7 weeks ago

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

Dec 16, 2025, 8:00 AM EST - 2 months ago

Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Nov 20, 2025, 8:00 AM EST - 3 months ago

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Nov 13, 2025, 8:00 AM EST - 3 months ago

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:21 PM EST - 3 months ago

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:00 AM EST - 3 months ago

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Nov 10, 2025, 8:00 AM EST - 3 months ago

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Nov 6, 2025, 8:00 AM EST - 3 months ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Oct 30, 2025, 8:00 AM EDT - 3 months ago

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Oct 7, 2025, 9:00 AM EDT - 4 months ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Oct 6, 2025, 8:00 AM EDT - 4 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Sep 29, 2025, 8:00 AM EDT - 4 months ago

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Sep 18, 2025, 7:00 AM EDT - 5 months ago

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Sep 15, 2025, 7:00 AM EDT - 5 months ago

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

Aug 12, 2025, 1:20 PM EDT - 6 months ago

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 10:00 AM EDT - 6 months ago

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 7:00 AM EDT - 6 months ago

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Jul 23, 2025, 8:00 AM EDT - 7 months ago

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Jul 8, 2025, 8:00 AM EDT - 7 months ago

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Humacyte: Revenue Ramp From Symvess Incoming

Jun 11, 2025, 9:05 AM EDT - 8 months ago

Humacyte: Revenue Ramp From Symvess Incoming

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Jun 9, 2025, 8:00 AM EDT - 8 months ago

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Jun 2, 2025, 8:00 AM EDT - 9 months ago

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

May 19, 2025, 4:05 PM EDT - 9 months ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

May 13, 2025, 2:29 PM EDT - 9 months ago

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 9 months ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

May 9, 2025, 8:00 AM EDT - 10 months ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Mar 28, 2025, 1:48 PM EDT - 11 months ago

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 28, 2025, 7:30 AM EDT - 11 months ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Mar 26, 2025, 8:00 AM EDT - 11 months ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Mar 25, 2025, 8:35 PM EDT - 11 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Mar 25, 2025, 4:01 PM EDT - 11 months ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Trestle Bio Announces Research Collaboration with Humacyte

Mar 6, 2025, 8:00 AM EST - 1 year ago

Trestle Bio Announces Research Collaboration with Humacyte

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Mar 3, 2025, 8:00 AM EST - 1 year ago

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 4:05 PM EST - 1 year ago

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Feb 27, 2025, 8:00 AM EST - 1 year ago

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Feb 26, 2025, 8:00 AM EST - 1 year ago

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Feb 20, 2025, 1:35 PM EST - 1 year ago

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Jan 21, 2025, 8:00 AM EST - 1 year ago

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Jan 17, 2025, 10:30 AM EST - 1 year ago

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rolf1968
Rolf1968 Feb. 15 at 12:42 AM
$HUMA off the shelf biological conduit is the holy grail
0 · Reply
MeetMillz732
MeetMillz732 Feb. 14 at 4:33 PM
$HUMA Humacyte (HUMA) Valuation Check As DoD Funding Highlights Battlefield Vascular Repair Potential https://share.google/qFc33zd7PXNCp7Yn5
0 · Reply
Q12021Dreaming
Q12021Dreaming Feb. 14 at 2:54 PM
$HUMA - Shorts are betting on a dilution death spiral that DoD funding ELIMINATED. They're fighting the: U.S. Department of Defense Congressional mandate FDA-approved monopoly $77.5M credit facility Battle-tested technology At $1.01, with 20.77% short interest, this is a ticking time bomb. When shorts realize they can't win, the covering cascade will be EPIC.
1 · Reply
fatpie68
fatpie68 Feb. 14 at 12:23 PM
$HUMA Institutional Ownership increased 1.43% over the past week.
0 · Reply
thrivegan86
thrivegan86 Feb. 14 at 2:09 AM
$HUMA = 100% of my portfolio. Boom or bust!
1 · Reply
Invest2live
Invest2live Feb. 14 at 12:01 AM
$ELUT 51% in a month already; congrats 🌿🎈🌿 Checkout $HUMA and $GERN
0 · Reply
Bad_Choices
Bad_Choices Feb. 13 at 10:48 PM
$HUMA it will just bar code around this area for a while until news.
0 · Reply
fordsurf
fordsurf Feb. 13 at 8:27 PM
$HUMA Sitting on 3300 at $6.25. Thinking it’s about time to start avg down. Come april / may…forget about it.
1 · Reply
BZT777
BZT777 Feb. 13 at 8:16 PM
$HUMA The big boys continued to add more HUMA in Q4 2025
0 · Reply
Bio_Be_Dirty
Bio_Be_Dirty Feb. 13 at 6:58 PM
$HUMA sales starting to pile
0 · Reply
jllpz
jllpz Feb. 13 at 6:40 PM
$HUMA Company with BIG POTENTIAL can pop any time
1 · Reply
MeetMillz732
MeetMillz732 Feb. 13 at 5:10 PM
$HUMA i think we can all agree that once this runs either negative or positive its going to be massive ... from the fda report alone I believe it will be massive in a positive way unless the company announcing some offerings or bs its no reason this doesnt Go To The Moon ... im here for the long Hual ... lets get it
1 · Reply
Invest2live
Invest2live Feb. 13 at 4:39 PM
$CPRI $MU $ON $MU 500% in less than a year. $IONQ and $HUMA has similar potential; do your DD and get in.
1 · Reply
Invest2live
Invest2live Feb. 13 at 4:36 PM
$GOSS 161% already; congrats 🎈 🎊🎉 Similar potential $HUMA and $QSI
1 · Reply
Invest2live
Invest2live Feb. 13 at 4:16 PM
$GERN 15% already; congrats 🎉 🎊🎈 Checkout $HUMA and $IMUX; can double from here.
2 · Reply
Diefreeandsell
Diefreeandsell Feb. 13 at 3:15 PM
$HUMA at support /bottom, downtrend turned sideways. Resitance at 50DMA @$1.08! Don't fall! Pull damn it!
0 · Reply
APman
APman Feb. 13 at 2:36 PM
$HUMA Humbly requesting one more dip below $1..
2 · Reply
Diefreeandsell
Diefreeandsell Feb. 13 at 2:36 PM
$HUMA Keep pulling/buying and don't let go till cross over at least $5! $1 is just for losers!
0 · Reply
Q12021Dreaming
Q12021Dreaming Feb. 13 at 2:18 PM
$HUMA Why Buy at $1.00 1. MONOPOLY + FDA APPROVAL Only FDA-approved bioengineered vascular product (December 2024) First-in-class, zero competition Proven efficacy: 16/16 patients survived in Ukraine (100% survival, zero amputations, zero infections) 2. "HISTORIC" PENTAGON FUNDING (AMOUNT UNDISCLOSED) DoD FY 2026 Appropriations Act includes dedicated funding CEO called it "historic, first-of-its-kind federal investment" Congressional appropriation (not routine contract) suggests $50M-$150M+ likely Binary catalyst pending - announcement could come any time 3. GUARANTEED GOVERNMENT REVENUE PIPELINE DoD contract = locked-in revenue (vs. uncertain hospital adoption) VA system access: 1,000+ facilities with procurement approval Potential for strategic military stockpiling worldwide 4. COMMERCIAL TRACTION BUILDING 34 hospitals in approval process, 3 already approved Price: $29,500 per unit 5. SHORT SQUEEZE SETUP 20.77% short interest + 7.31 days to cover
1 · Reply
Q12021Dreaming
Q12021Dreaming Feb. 13 at 4:56 AM
$HUMA = Looks like .88 is the bottom, What's the top?
1 · Reply
Q12021Dreaming
Q12021Dreaming Feb. 13 at 2:29 AM
$HUMA - My estimate for the next week (assuming the Pentagon announcement hits early and momentum sustains): $1.30-$1.60 per share is realistic. This assumes a 25-55% spike from current ~$1.03 levels, blending the recent 30% reaction with precedents like MP's 50%. Short Squeeze is a real factor. This is purely speculative—biotech micro-caps can swing wildly, and past performance isn't indicative. Monitor volume and short data for confirmation. Invest at your own risk, do your own due dilegince!
1 · Reply
bioman2024
bioman2024 Feb. 13 at 1:43 AM
$HUMA …Aside from the share price, if this technology continues to prove out, it will be transformational. The world needs it. This platform needs to be accelerated.
0 · Reply